Biomarkers Predict Brain Tumor’s Response to Therapy
•	MRI and blood biomarkers predict benefit of antiangiogenic therapy •	Greater blood vessel
normalization associated with longer survival •	Patients with the 25 percent highest
normalization lived about a year longer
Philadelphia (Vocus) – A report in Cancer Research, a journal of the American Association for Cancer Research,
highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain
tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It
is an investigational, oral agent that is administered once daily. Using a form of magnetic resonance imaging
(MRI) that looked at the mechanism of action of this agent, the researchers were able to determine, even as early
as after a single dose of cediranib, those patients who benefited from the agent and those who did not.
“We found that results from an advanced MRI scan taken just a day after starting treatment correlated with
survival. Combining MRI with blood biomarkers did an even better job of identifying patients who best
responded to treatment,” said researcher A. Gregory Sorensen, M.D., associate professor of radiology and health
sciences and technology at Harvard Medical School, Massachusetts General Hospital. “If this approach is
validated in larger studies, we could use these tools to keep patients on therapies that their tumors respond to, and
shift non-responders to other therapies much earlier.”
Sorensen and colleagues sought to find the potential biomarkers that could be used to predict those patients who
would respond better from antiangiogenic therapy early in the course of treatment by use of MRI.
The researchers measured vascular normalization prior to and one day after patients’ received cediranib using an
advanced MRI technique. They performed blood analysis and examined co